Literature DB >> 7310640

Dose dependent pharmacokinetics of prednisone and prednisolone in man.

J Q Rose, A M Yurchak, W J Jusko.   

Abstract

Six healthy male volunteers were given 5, 20, and 50 mg of oral prednisone and 5, 20, and 400 mg doses of intravenous prednisolone. Plasma and urine concentrations of prednisone and prednisolone were determined by HPLC, and the binding of prednisolone to plasma proteins was measured by radioisotopic and equilibrium dialysis techniques. The pharmacokinetics of both oral prednisone and intravenous prednisolone were dose-dependent. The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose. Changes in prednisone half-life were insignificant, but increases in the half-life of its metabolite were dose-dependent. The systemic plasma clearance of i.v. prednisolone was dose-dependent and increased from 111 to 194 ml/min/1.73 m 2 over the 5 to 40 mg i.v. dosage range. The steady-state volume of distribution also increased, but little change in mean transit time and half-life was found. The binding of prednisolone to plasma proteins was markedly concentration-dependent, and a two compartment, nonlinear equation was used to characterize the effective binding of prednisolone to transcortin and albumin. The apparent pharmacokinetic parameters of protein-free and transcortin-free prednisolone were relatively constant with dose. The interconversion of prednisone and prednisolone varied with time and dose, although prednisolone concentrations dominated by 4- to 10-fold over prednisone. In urine, 2-5% of either administered drug was excreted as prednisone and 11-24% as prednisolone. The apparent renal clearances of both steroids were also nonlinear and unrelated to protein binding. These studies indicate that the pharmacokinetics of prednisone and prednisolone are dose-dependent and that protein binding does not fully explain their apparent nonlinear distribution and disposition.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7310640     DOI: 10.1007/bf01060885

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  41 in total

1.  INFLUENCE OF VARIOUS STEROIDS ON THE SPECIFIC BINDING OF CORTISOL.

Authors:  P DEMOOR; R DECKX; O STEENO
Journal:  J Endocrinol       Date:  1963-11       Impact factor: 4.286

2.  Ultrafiltration studies of steroid-protein binding.

Authors:  P S CHEN; I H MILLS; F C BARTTER
Journal:  J Endocrinol       Date:  1961-10       Impact factor: 4.286

3.  Increased oxidation of phenylbutazone during hydrocortisone infusion in man.

Authors:  J Aarbakke; M R Bending; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

4.  Dose-dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J C Loo; I J McGilveray; N Jordan; J Moffat; R Brien
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

5.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

6.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

7.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

8.  Serum protein binding of prednisolone in four species.

Authors:  M L Rocci; N F Johnson; W J Jusko
Journal:  J Pharm Sci       Date:  1980-08       Impact factor: 3.534

9.  Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone.

Authors:  W A Hsueh; A Paz-Guevara; T Bledsoe
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

10.  Metabolic clearance rate and interconversion of androgens and the influence of the free androgen fraction.

Authors:  A Vermeulen; S Andó
Journal:  J Clin Endocrinol Metab       Date:  1979-02       Impact factor: 5.958

View more
  52 in total

1.  Steroid metabolism in liver transplant patients.

Authors:  R Venkataramanan; M L Huang; B Delamos; G J Burckart; R J Ptachcinski; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Prednisone Pharmacokinetics During Pregnancy and Lactation.

Authors:  Rachel J Ryu; Thomas R Easterling; Steve N Caritis; Raman Venkataramanan; Jason G Umans; Mahmoud S Ahmed; Shannon Clark; Ira Kantrowitz-Gordon; Karen Hays; Brooke Bennett; Matthew T Honaker; Kenneth E Thummel; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2018-05-07       Impact factor: 3.126

3.  Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats.

Authors:  M L Huang; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

4.  Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man.

Authors:  J A Wald; R M Law; E A Ludwig; R R Sloan; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

5.  Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.

Authors:  Marija Tubic-Grozdanis; Michael B Bolger; Peter Langguth
Journal:  AAPS J       Date:  2008-04-02       Impact factor: 4.009

Review 6.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 7.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

8.  Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Authors:  Panteleimon D Mavroudis; John van den Anker; Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; Kanneboyina Nagaraju; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2019-02-11       Impact factor: 3.126

9.  Pharmacokinetics of antiviral polyoxometalates in rats.

Authors:  L Ni; F D Boudinot; S G Boudinot; G W Henson; G E Bossard; S A Martellucci; P W Ash; S P Fricker; M C Darkes; B R Theobald
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Disposition of prednisone and prednisolone in the perfused rabbit liver: modeling hepatic metabolic processes.

Authors:  V G Hale; K Aizawa; L B Sheiner; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1991-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.